JP2014156484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014156484A5 JP2014156484A5 JP2014108085A JP2014108085A JP2014156484A5 JP 2014156484 A5 JP2014156484 A5 JP 2014156484A5 JP 2014108085 A JP2014108085 A JP 2014108085A JP 2014108085 A JP2014108085 A JP 2014108085A JP 2014156484 A5 JP2014156484 A5 JP 2014156484A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer cells
- receptor antagonist
- cancer
- human prolactin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15562409P | 2009-02-26 | 2009-02-26 | |
| US61/155,624 | 2009-02-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Division JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014156484A JP2014156484A (ja) | 2014-08-28 |
| JP2014156484A5 true JP2014156484A5 (https=) | 2015-04-16 |
Family
ID=42133705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Expired - Fee Related JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
| JP2014108085A Pending JP2014156484A (ja) | 2009-02-26 | 2014-05-26 | がん幹細胞を可視化・排除するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Expired - Fee Related JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8754035B2 (https=) |
| EP (1) | EP2400979B1 (https=) |
| JP (2) | JP5963443B2 (https=) |
| KR (1) | KR101672401B1 (https=) |
| CN (2) | CN106177954A (https=) |
| AU (1) | AU2010218261B2 (https=) |
| CA (1) | CA2753804C (https=) |
| IL (2) | IL214545A (https=) |
| WO (1) | WO2010099003A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8648046B2 (en) * | 2009-02-26 | 2014-02-11 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
| EP2576823A1 (en) * | 2010-06-04 | 2013-04-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence |
| CN105102480B (zh) | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| EP3157547A1 (en) * | 2014-06-18 | 2017-04-26 | Prorec Bio AB | Prolactin receptor antagonists for treatment of glioblastoma |
| CN107198779A (zh) * | 2016-11-29 | 2017-09-26 | 南京东纳生物科技有限公司 | 一种干细胞标记示踪及靶向导航的纳米偶联复合物及其制备方法和应用 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| WO2020011998A1 (en) * | 2018-07-13 | 2020-01-16 | Hifibio Sas | Use of droplet single cell epigenome profiling for patient stratification |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1055932A (en) | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
| DE2616086C2 (de) | 1976-04-13 | 1986-04-03 | Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg | Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin |
| EP1079851B1 (en) | 1998-05-12 | 2007-07-04 | Greenville Hospital System | Use of anti-prolactin agents to treat cancer |
| EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP1282642B1 (en) | 2000-05-09 | 2006-09-06 | Greenville Hospital System | Therapeutic pore-forming peptides |
| EP1411922A1 (en) * | 2001-07-31 | 2004-04-28 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
| US7001888B2 (en) * | 2002-03-29 | 2006-02-21 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| BR0314106A (pt) | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Polipeptìdeos hasilados, especialmente eritropoietina hasilada |
| NZ541122A (en) * | 2002-12-26 | 2008-09-26 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US20050238628A1 (en) * | 2004-04-08 | 2005-10-27 | Blau Carl A | Methods for treating cancer |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| WO2009089537A2 (en) * | 2008-01-11 | 2009-07-16 | Northwestern University | Anti-cancer compounds |
-
2010
- 2010-02-16 US US12/706,702 patent/US8754035B2/en not_active Expired - Fee Related
- 2010-02-16 WO PCT/US2010/024340 patent/WO2010099003A2/en not_active Ceased
- 2010-02-16 AU AU2010218261A patent/AU2010218261B2/en not_active Ceased
- 2010-02-16 CA CA2753804A patent/CA2753804C/en not_active Expired - Fee Related
- 2010-02-16 EP EP20100705493 patent/EP2400979B1/en not_active Not-in-force
- 2010-02-16 KR KR1020117022422A patent/KR101672401B1/ko not_active Expired - Fee Related
- 2010-02-16 CN CN201610657107.2A patent/CN106177954A/zh active Pending
- 2010-02-16 CN CN2010800089960A patent/CN102341118A/zh active Pending
- 2010-02-16 JP JP2011552066A patent/JP5963443B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-09 IL IL214545A patent/IL214545A/en not_active IP Right Cessation
-
2014
- 2014-05-26 JP JP2014108085A patent/JP2014156484A/ja active Pending
-
2016
- 2016-06-15 IL IL246247A patent/IL246247A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014156484A5 (https=) | ||
| McCubrey et al. | Targeting breast cancer initiating cells: advances in breast cancer research and therapy | |
| Faustino-Rocha et al. | Antihistamines as promising drugs in cancer therapy | |
| Brufsky et al. | RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. | |
| JP2015530399A5 (https=) | ||
| Izar et al. | Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer | |
| JP2018512443A5 (https=) | ||
| CN109475535A (zh) | 癌症的联合治疗 | |
| WO2016022939A8 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
| JP2017031059A (ja) | がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤 | |
| Zeino et al. | Cytotoxicity of cardiotonic steroids in sensitive and multidrug-resistant leukemia cells and the link with Na+/K+-ATPase | |
| JP2014523398A5 (https=) | ||
| WO2017053555A8 (en) | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs | |
| MX2019012044A (es) | Vacuna para enfermedad intrauterina. | |
| JP2015506352A5 (https=) | ||
| Kim et al. | Novel alkylaminopyridazine derivatives: Synthesis and their anti-proliferative effects against MCF-7 cells | |
| WO2015026934A8 (en) | Bruton's tyrosine kinase as anti-cancer drug target | |
| CN203682011U (zh) | 一种兽药可溶性粉剂分装铲 | |
| Ainscow et al. | CT7001: An orally bioavailable CDK7 inhibitor is a potential therapy for breast, small-cell lung and haematological cancers | |
| Banerjee et al. | Combination of metformin and metronomic liposomal doxorubicin exerts a robust anticancer effect in triple negative breast cancer by inhibiting breast cancer stem cells & the Wnt/beta-catenin pathway | |
| Nakhjavani et al. | Studying the effect of methylparaben and propylparaben on growth curve of human breast adenocarcinoma cell line | |
| Hughes et al. | Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629 | |
| Chen et al. | Abstract B21: Novel pateamine A analogs to target pro-survival proteins in chronic lymphocytic leukemia | |
| Porru et al. | The G-quadruplex ligand EMICORON potentiates the antitumor efficacy of chemotherapy on colon cancer experimental models | |
| Jie | Opportunities of Inner Mongolia's economic development under the background of the “Silk Road Economic Belt” |